241P Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors

DLL3, a type I transmembrane protein that serves as an inhibitor in the Notch pathway, is a validated target for direct therapy. It exhibits significant upregulation and abnormal expression on the cell surface in small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors, promoting SCLC migration and invasion.